Antimicrobial resistance (AMR) is one of the most pressing global health crises today. It is an emerging cause of Healthcare Associated Infections (HAI), posing a significant threat to public health. The rising prevalence of resistance to antibiotics, particularly to carbapenems, is driven by the increase in multidrug-resistant pathogens. This emergence and spread of drug-resistant pathogens jeopardise our ability to treat common infections and perform life-saving medical procedures.
The impact of AMR on healthcare cannot be overstated:
- Infections become harder to treat.
- Medical procedures and treatments become significantly riskier.
- AMR could lead to an additional $1trn in healthcare costs by 2050.
- Drug-resistant infections also impact animal and plant health, threatening food security.
Detecting carbapenemases-mediated carbapenem resistance is crucial for effective patient management, infection control and public health initiatives. Early detection helps curb the spread of resistant strains, protecting both individual patients and broader communities.
Certest’s Carbapenemases Rapid Test is a multiplex immunochromatographic professional IVD test designed for rapid and reliable detection of the five most frequently identified carbapenemases in CRE: KPC, NDM, VIM, OXA-48-type and IMP. Choosing the right carbapenemases detection test depends on several factors, including local prevalence, regional molecular epidemiology, diagnostic performance, labour intensity, cost and turnaround time.
Certest’s rapid test for carbapenemases detection is an indispensable tool in the fight against AMR. By providing fast and accurate results, it enables healthcare providers to implement timely infection control measures, ultimately reducing the spread of resistant pathogens and safeguarding public health.
